Thanks BDAZ that is exactly the way I understand the outcome. I get butterflies thinking about getting 27% or 28% RRR and remembering what happened to our share price in 2013 when we got .4% plaque regression versus .6% which was the trials prestated goal. Having to do another study wouldn't be the end of the world but would require a recapitalization.
All IMO, dyoddÂ
tada